Abstract
In the past years, the scientific literatures have reported dozens of molecular alterations in autism spectrum disorder (ASD) . However, limitations of these studies were the lack of reproducibility, which could be due to the fact that few studies succeeded to account for heterogeneity. Therefore, biological stratification that clarifies biological heterogeneity within ASD will be beneficial in discovering the biological mechanisms of ASD.
The current review paper will overview the previous blood marker research on ASD, and eventually we will discuss the blood marker’s ability to assess the therapeutic effect, given the case of novel candidate therapeutic molecule for ASD, oxytocin.
